stoxline Quote Chart Rank Option Currency Glossary
Praxis Precision Medicines, Inc. (PRAX)
41.64  1.31 (3.25%)    02-23 16:00
Open: 40.96
High: 42.8099
Volume: 84,601
Pre. Close: 40.33
Low: 40.05
Market Cap: 524(M)
Technical analysis
2024-02-23 4:38:54 PM
Short term     
Mid term     
Targets 6-month :  50.68 1-year :  56.41
Resists First :  43.39 Second :  48.29
Pivot price 42.42
Supports First :  35.45 Second :  29.49
MAs MA(5) :  40.89 MA(20) :  42.06
MA(100) :  25.77 MA(250) :  20.86
MACD MACD :  1.6 Signal :  2.6
%K %D K(14,3) :  20.7 D(3) :  21.4
RSI RSI(14): 55.9
52-week High :  52.65 Low :  11.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PRAX ] has closed above bottom band by 38.9%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 42.85 - 43.06 43.06 - 43.24
Low: 39.57 - 39.8 39.8 - 40
Close: 41.29 - 41.65 41.65 - 41.97
Company Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Headline News

Tue, 13 Feb 2024
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is definitely on the radar of institutional investors who own 47% of ... - Yahoo Finance

Fri, 02 Feb 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barron's

Thu, 11 Jan 2024
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering - Yahoo Finance

Wed, 10 Jan 2024
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - GlobeNewswire

Tue, 09 Jan 2024
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Mon, 08 Jan 2024
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 13 (M)
Held by Insiders 6.13e+006 (%)
Held by Institutions 0.2 (%)
Shares Short 371 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.3759e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 452.1 %
Return on Equity (ttm) -70.9 %
Qtrly Rev. Growth 1.93e+006 %
Gross Profit (p.s.) 0
Sales Per Share -49.79
EBITDA (p.s.) 0
Qtrly Earnings Growth -29.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -116 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0.1
Price to Book value 0
Price to Sales -0.84
Price to Cash Flow 11.85
Stock Dividends
Dividend 0
Forward Dividend 563950
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android